Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today

GlobeNewswireMay 14 04:30

Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...

Yahoo FinanceMay 11 03:12

Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion

TipRanksMay 10 13:31

HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $54 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $54 price target.

BenzingaMay 10 03:24

Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham

Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham

Dow JonesMay 8 23:50

Needham: Reiterates Cartesian Therapeutics (RNAC.US) rating and adjusted from buy to buy rating, target price is $42.00.

Needham: Reiterates Cartesian Therapeutics (RNAC.US) rating and adjusted from buy to buy rating, target price is $42.00.

Zhitong FinanceMay 8 23:40